Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. - Wikidata - awgldk - TriplyDB

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

http://www.wikidata.org/entity/Q43270036

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Trial watch - inhibiting PARP enzymes for anticancer therapy First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer National consensus in China on diagnosis and treatment of patients with advanced breast cancer Optimal management of hormone receptor positive metastatic breast cancer in 2016 Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer Targeting RTK Signaling Pathways in Cancer More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer Health economic aspects of breast cancer treatment: the compulsory health insurances' view Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Newer therapies for the treatment of metastatic breast cancer: a clinical update Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options The sequential use of endocrine treatment for advanced breast cancer: where are we?Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Optimal management of breast cancer in the elderly patient: current perspectives Approaches to modernize the combination drug development paradigm Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant Twenty years of anti-HER2 therapy-associated cardiotoxicity Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01 Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Hematologic toxicities of small molecule tyrosine kinase inhibitors.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

P2860

Q21284978-FB79AF1D-0E3B-469D-A9D0-6388CE6ED2BC Q26745673-E65E4515-8653-419C-844F-5838F269EA26 Q26746081-B0202D48-EA7A-4DB5-8D45-79968E19DB4A Q26752780-C078BCD1-703D-417B-A064-B604488B3970 Q26752834-343B2B07-52AE-4D16-A61C-BD38AD699BA8 Q26764987-32AE2C4C-1B15-463B-9BB7-86A65EDDE27E Q26772969-A6746EC2-CF41-4BA9-A37C-A93EEFDCEB21 Q26775621-5A0E6C4D-A652-49E0-8A93-BDD14ECF3E22 Q26777683-7E98F00C-0CE8-4A10-BF3B-F75B2F96400D Q26777734-8D0B0896-A92F-479C-9B5E-1BEB4F7FBEF9 Q26781278-336471D6-6B64-41D9-80D5-AA87D4B76FEC Q26781662-6A822546-95D4-464B-B06D-DEF23CC67A16 Q26785496-4C7B8678-2070-4BB7-BD8A-44FEA3C95D37 Q26824799-F5333FC4-2B02-4EE1-9ACA-CD5BB4199584 Q26826505-8EE6A352-33AB-467E-AFDC-51DBCACE6D58 Q26862550-2D7793D2-C6AF-431F-99D6-AEFD30D06091 Q26865260-4248624C-024F-4BC3-A201-FAF2785DC320 Q26995549-B574D71B-0409-4BA6-A4FA-B2698A5FDDA2 Q26997396-A132F158-EBCD-4BCC-A17E-3D9B905DA673 Q27001260-F63B36B5-4DAD-4947-AC4B-6F87B0BA28AD Q27025863-3955F7AA-8550-48E9-B82A-8089FFACE3E1 Q27690879-E6C54BAD-048F-4F31-ADE2-8FC43CA503DD Q28072074-287E9F1D-BCFA-4A67-9D39-9E8D27D8DE1D Q28072766-883F9699-BF75-4358-954C-BAB13FDECDA7 Q28072897-F88DA850-C9E8-4A4E-89C0-94AFF765537C Q28076777-9AEC45F7-8B66-487D-9ACE-692C85EA9515 Q28079391-A9A4C1F5-5825-4D37-AB77-8FC3A89C19DF Q28084585-1C73C614-0359-4EAF-BF22-08D7ACD62BCB Q28547354-4E92E4C8-167B-4025-A12F-C92970A40F9A Q28548544-CC16CEDC-E77B-4E3E-A33E-623983E3AB7D Q30249335-AECB340B-3595-40BD-8272-5FD8AEEA1C67 Q30318823-611F8DB9-C66E-4692-B4F7-3A65A7FB5860 Q31134061-E2BE48D9-28E3-43A4-A41F-69E25E1AA612 Q33398485-149077BB-498A-47ED-876A-1E6258878EF7 Q33409083-9B2195E3-7621-4F9F-91EF-856CAA1081A2 Q33579653-128AED63-3363-441E-9A7B-2D56D66DB039 Q33597447-037A75DB-4FD7-4BAE-BAEE-6307E85377C2 Q33600072-4B3E6B35-1B2C-46FC-96D4-3C4DD5402518 Q33629947-3F2B13F0-A6F2-48F9-A21F-0516F8A05501 Q33648503-8D66ED00-DF6B-4C68-A88E-60D479414BCC

P2860

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

http://www.wikidata.org/entity/Q43270036

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@en

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@nl

type

label

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@en

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@nl

prefLabel

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@en

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@nl

P1433

Q43270036-45882F24-F90F-4D71-BC9E-450FDE1275B7

P1476

Q43270036-8B19ABE1-437D-4EAF-BF2B-5D1E10331835

P2093

Q43270036-04183A52-354E-4A66-9DDF-672976FC0729

Q43270036-1CE3E638-837C-4A16-BFDC-7BFFFE2C24B9

Q43270036-56670A1C-D8AB-4C8D-B00C-E99FD654AB29

Q43270036-59614C73-8440-4186-9A2D-333FAC4F97FF

Q43270036-6153AF92-296E-411A-96D0-6ABEEE5917FF

Q43270036-6365C545-E384-4026-8941-3723C50D27AE

Q43270036-7C85E4B7-8E6E-436C-BABC-142B377F91D1

Q43270036-8FC9B4A7-87AE-471B-B0AA-0322C7F77B78

Q43270036-9882A8F1-F5B8-4D34-957B-54CC39EEE770

Q43270036-9C126619-5F95-46AC-8D6A-CC667DB9A255

P304

Q43270036-7F96E464-E8F2-49E4-B771-423D2EE85DF0

P31

Q43270036-44BCEB7B-9604-4FB8-9347-8DFEC44C52BA

P356

Q43270036-89E3C821-FF3B-41C9-9A7A-F51820D91ADB

P407

Q43270036-774B7224-4C59-4FB4-BD71-92A1E6430A90

P433

Q43270036-AA13F53D-9425-4C4A-8C63-34B940886758

P478

Q43270036-653579F9-FA8E-4535-9A04-80B33FA2CF36

P50

Q43270036-21A28400-9B6F-4FE2-8930-5A8F51202745

P577

Q43270036-2E12C793-87E1-4DC9-9379-847745138FA7

P5875

Q43270036-0A32872A-D807-4C15-B59A-4AFBAF73B957

P698

Q43270036-DF9991B4-5A48-4B2E-B0FD-72EC3719E69C

P921

Q43270036-4D9798C8-4A39-4C1B-8D86-C2258D692B48

P356

JCO.2009.23.3734

P1433

Journal of Clinical Oncology

P1476

Lapatinib combined with letroz ...... tive metastatic breast cancer.

@en

P2093

Alexey Manikhas

http://www.w3.org/2001/XMLSchema#string

Allison Florance

http://www.w3.org/2001/XMLSchema#string

Cristina Oliva

http://www.w3.org/2001/XMLSchema#string

Gilles Romieu

http://www.w3.org/2001/XMLSchema#string

John Pippen

http://www.w3.org/2001/XMLSchema#string

Julie Maltzman

http://www.w3.org/2001/XMLSchema#string

Lisa O'Rourke

http://www.w3.org/2001/XMLSchema#string

M John Kennedy

http://www.w3.org/2001/XMLSchema#string

Mark Pegram

http://www.w3.org/2001/XMLSchema#string

Michael F Press

http://www.w3.org/2001/XMLSchema#string

P304

5538-5546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.23.3734

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Henry Leonidas Gomez

P577

2009-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26853593

http://www.w3.org/2001/XMLSchema#string

P698

19786658

http://www.w3.org/2001/XMLSchema#string

P921